Back to results
US 2025/0375315 A1Published application
Method and device for treating and managing diseased ocular tissue
OwnerSara Heikali, Moossa Heikaliinventors
Life of this patent
Estimating the term…
Abstract
A method comprises treating an ocular condition resulting from an MMP imbalance comprising: applying to the ocular tissue an effective amount of a therapeutic composition, wherein said therapeutic composition comprises a first MMP inhibitor comprising EDTA.
Claims20
A method of treating an ocular condition resulting from an MMP imbalance comprising:
- applying to the ocular tissue an effective amount of a therapeutic composition,
- wherein said therapeutic composition comprises a first MMP inhibitor comprising EDTA.
A method of treating an ocular condition comprising,
- i) creating a plurality of micro-injury sites in the ocular tissue;
- and
- ii) applying an effective amount of a therapeutic composition to the micro-injury sites,
- wherein said therapeutic composition comprises a first MMP inhibitor comprising EDTA.
1 more element
A contact lens comprising a therapeutic composition comprising a first MMP inhibitor comprising EDTA.
A method of treating an ocular condition comprising the steps of:
- administering to the eye of a subject in need thereof a therapeutic composition comprising
- (a) a first MMP inhibitor comprising 0.1%-10.0% (wt.) EDTA or a derivative, analog, or pharmaceutically acceptable salt thereof;
- (b) a second MMP inhibitor comprising 0.1%-10% (wt.) of an MMP9 inhibitor, wherein the first MMP inhibitor and second MMP inhibitor are different;
- and
- wherein the administration of a unit dose of the therapeutic composition comprises a single eye drop providing sustained release of the first MMP inhibitor or derivative, analog, or pharmaceutically acceptable salt thereof and the second MMP inhibitor, in the eye for at least two days and administration is repeated at least once every day.
2 more elements
Dependencies are inferred from the claim text.